Abstract: The invention provides compositions and in vivo, ex vivo and in vitro methods for trans-differentiation of or re-programming mammalian cells to functional neurons. In particular, the invention provides methods for engineering non-neuronal cells into neurons, including fully functional human neuronal cells, and methods for engineering non-neuronal cells into neurons, e.g., fully functional human neuronal cells, in the brain to treat a neurodegenerative disease. In alternative embodiments, the invention provides compositions comprising re-differentiated or re-programmed mammalian cells, such as human cells, of the invention. The invention also provides compositions and methods for direct reprogramming of cells to a second phenotype or differentiated phenotype, such as a neuron, including a fully functional human neuronal cell.

Abstract: Provided herein is a method of reprogramming a non-neuronal cell to a neuron. Aspects of the present disclosure relate to using cell reprogramming agent suppresses the expression or activity of PTB to convert a non-neuronal cell into a neuron. Also provided herein is a method of treating neurodegenerative disease by reprogramming non-neuronal cells in vivo to functional neurons.

Abstract: Provided herein are compositions and methods for reprogramming a non-neuronal cell to a neuron. Aspects of the present disclosure relate to compositions and methods for transdifferentiating an age-restricted non-neuronal cell into a neuron. Also provided herein is a method of treating neurodegenerative disease by reprogramming region or anatomy specific non-neuronal cells into specific types of functionalized neurons.

Abstract: A method to detect chromatin-interacting RNAs in any given state of a cell or tissue by examining global RNA interactions with DNA by deep sequencing. A method to generate a global view of chromatin-RNA interactome by mapping the binding locations on the genome of each detected chromatin interacting RNA.

Abstract: Provided herein is a method of reprogramming a non-neuronal cell to a neuron. Aspects of the present disclosure relate to using cell reprogramming agent suppresses the expression or activity of PTB to convert a non-neuronal cell into a neuron. Also provided herein is a method of treating neurodegenerative disease by reprogramming non-neuronal cells in vivo to functional neurons.

Abstract: The invention provides compositions and in vivo, ex vivo and in vitro methods for trans-differentiation of or re-programming mammalian cells to functional neurons. In particular, the invention provides methods for engineering non-neuronal cells into neurons, including fully functional human neuronal cells, and methods for engineering non-neuronal cells into neurons, e.g., fully functional human neuronal cells, in the brain to treat a neurodegenerative disease. In alternative embodiments, the invention provides compositions comprising re-differentiated or re-programmed mammalian cells, such as human cells, of the invention. The invention also provides compositions and methods for direct reprogramming of cells to a second phenotype or differentiated phenotype, such as a neuron, including a fully functional human neuronal cell.

Abstract: A method to detect chromatin-interacting RNAs in any given state of a cell or tissue by examining global RNA interactions with DNA by deep sequencing. A method to generate a global view of chromatin-RNA interactome by mapping the binding locations on the genome of each detected chromatin interacting RNA.

Abstract: The invention provides products of manufacture for screening for compositions that can modify a cell's gene expression profile, and methods for making and using them. In one embodiment, the invention provides products of manufacture and methods comprising a high content, high throughput screening for a composition (e.g., chemicals, small molecules) that can modify a cell's physiology based on the composition's ability to modify the cell's gene expression signature.

Abstract: The invention provides compositions and in vivo, ex vivo and in vitro methods for trans-differentiation of or re-programming mammalian cells to functional neurons. In particular, the invention provides methods for engineering non-neuronal cells into neurons, including fully functional human neuronal cells, and methods for engineering non-neuronal cells into neurons, e.g., fully functional human neuronal cells, in the brain to treat a neurodegenerative disease. In alternative embodiments, the invention provides compositions comprising re-differentiated or re-programmed mammalian cells, such as human cells, of the invention. The invention also provides compositions and methods for direct reprogramming of cells to a second phenotype or differentiated phenotype, such as a neuron, including a fully functional human neuronal cell.

Abstract: The invention provides products of manufacture for screening for compositions that can modify a cell's gene expression profile, and methods for making and using them. In one embodiment, the invention provides products of manufacture and methods comprising a high content, high throughput screening for a composition (e.g., chemicals, small molecules) that can modify a cell's physiology based on the composition's ability to modify the cell's gene expression signature.

Abstract: The disclosure provides methods and compositions useful for high throughput sequencing of nucleic acid sequences associated with gene expression, nucleic acid-polypeptide interactions, and/or chromosomal interactions.

Abstract: The disclosure provides methods of examining the binding of proteins to DNA across a genome (e.g., the entire genome or a portion thereof, such as one or more chromosomes or a chromosome regions). In particular, the disclosure relates to a method of identifying a regulatory region (e.g., a protein or enhancer region) of genomic DNA to which a protein of interest binds. In one aspect, the disclosure looks at tissue related regulation. In another aspect, the disclosure looks at developmental related regulation. In yet another aspect, the disclosure looks at regulation of expression in a particular disease state or disorder.

Abstract: The present invention is directed to providing sensitive and accurate assays for gene detection, genome-wide gene expression profiling and alternative splice monitoring with a minimum or absence of target-specific amplification.

Abstract: The disclosure provides methods of examining the binding of proteins to DNA across a genome (e.g., the entire genome or a portion thereof, such as one or more chromosomes or a chromosome regions). In particular, the disclosure relates to a method of identifying a regulatory region (e.g., a protein or enhancer region) of genomic DNA to which a protein of interest binds. In one aspect, the disclosure looks at tissue related regulation. In another aspect, the disclosure looks at developmental related regulation. In yet another aspect, the disclosure looks at regulation of expression in a particular disease state or disorder.

Abstract: The present invention is directed to providing sensitive and accurate assays for gene detection, genome-wide gene expression profiling and alternative splice monitoring wit a minimum or absence of target-specific amplification.

Abstract: The present invention is directed to providing sensitive and accurate assays for gene detection, genome-wide gene expression profiling and alternative splice monitoring with a minimum or absence of target-specific amplification.

Abstract: The present invention is directed to providing sensitive and accurate assays for gene detection, genome-wide gene expression profiling and alternative splice monitoring with a minimum or absence of target-specific amplification.

Abstract: A novel serine protein kinase, SRPK1, having a molecular weight of about 92 kD and phosphorylating the SR family of splicing factors in a cell-cycle regulated manner is described. Polynucleotide and polypeptide sequences for SRPK1 are provided as well as methods for modulating splicing and alternative splicing of precursor mRNAs.